Local delivery of anticancer agents has the potential to maximize treatment efficacy and minimize the acute and long-term systemic toxicities. Here, we used unsupervised systematic evolution of ligands by exponential enrichment to identify four RNA aptamers that specifically recognized mouse and human myeloid cells infiltrating tumors but not their peripheral or circulating counterparts in multiple mouse models and from patients with head and neck squamous cell carcinoma (HNSCC). The use of these aptamers conjugated to doxorubicin enhanced the accumulation and bystander release of the chemotherapeutic drug in both primary and metastatic tumor sites in breast and fibrosarcoma mouse models. In the 4T1 mammary carcinoma model, these doxorubicin-conjugated aptamers outperformed Doxil, the first clinically approved highly optimized nanoparticle for targeted chemotherapy, promoting tumor regression after just three administrations with no detected changes in weight loss or blood chemistry. These RNA aptamers recognized tumor infiltrating myeloid cells in a variety of mouse tumors in vivo and from human HNSCC ex vivo. This work suggests the use of RNA aptamers for the detection of myeloid-derived suppressor cells in humans and for a targeted delivery of chemotherapy to the tumor microenvironment in multiple malignancies.

Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy / De La Fuente, A.; Zilio, S.; Caroli, J.; Van Simaeys, D.; Mazza, E. M. C.; Ince, T. A.; Bronte, V.; Bicciato, S.; Weed, D. T.; Serafini, P.. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6242. - 12:548(2020), pp. eaav9760-eaav9766. [10.1126/scitranslmed.aav9760]

Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy

Caroli J.;Mazza E. M. C.;Bicciato S.;
2020

Abstract

Local delivery of anticancer agents has the potential to maximize treatment efficacy and minimize the acute and long-term systemic toxicities. Here, we used unsupervised systematic evolution of ligands by exponential enrichment to identify four RNA aptamers that specifically recognized mouse and human myeloid cells infiltrating tumors but not their peripheral or circulating counterparts in multiple mouse models and from patients with head and neck squamous cell carcinoma (HNSCC). The use of these aptamers conjugated to doxorubicin enhanced the accumulation and bystander release of the chemotherapeutic drug in both primary and metastatic tumor sites in breast and fibrosarcoma mouse models. In the 4T1 mammary carcinoma model, these doxorubicin-conjugated aptamers outperformed Doxil, the first clinically approved highly optimized nanoparticle for targeted chemotherapy, promoting tumor regression after just three administrations with no detected changes in weight loss or blood chemistry. These RNA aptamers recognized tumor infiltrating myeloid cells in a variety of mouse tumors in vivo and from human HNSCC ex vivo. This work suggests the use of RNA aptamers for the detection of myeloid-derived suppressor cells in humans and for a targeted delivery of chemotherapy to the tumor microenvironment in multiple malignancies.
2020
12
548
eaav9760
eaav9766
Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy / De La Fuente, A.; Zilio, S.; Caroli, J.; Van Simaeys, D.; Mazza, E. M. C.; Ince, T. A.; Bronte, V.; Bicciato, S.; Weed, D. T.; Serafini, P.. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6242. - 12:548(2020), pp. eaav9760-eaav9766. [10.1126/scitranslmed.aav9760]
De La Fuente, A.; Zilio, S.; Caroli, J.; Van Simaeys, D.; Mazza, E. M. C.; Ince, T. A.; Bronte, V.; Bicciato, S.; Weed, D. T.; Serafini, P.
File in questo prodotto:
File Dimensione Formato  
aav9760_ArticleContent_v5.docx

Accesso riservato

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 879.13 kB
Formato Microsoft Word XML
879.13 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1204540
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 19
social impact